Matthew Pauls

Matthew Pauls has an estimated net worth of $9.61 Million. This is based on reported shares across multiple companies, which include INSMED Inc, Strongbridge Biopharma plc, Zyla Life Sciences, Savara Inc, SOLENO THERAPEUTICS INC, and Pelthos Therapeutics Inc..

2021 was Matthew Pauls's most active year for acquiring shares with 13 total transactions. Matthew Pauls's most active month to acquire stocks was the month of November. 2025 was Matthew Pauls's most active year for disposing of shares, totalling 8 transactions. Matthew Pauls's most active month to dispose stocks was the month of November. 2014 saw Matthew Pauls paying a total of $992,100.00 for 60,000 shares, this is the most they've acquired in one year. In 2025 Matthew Pauls cashed out on 380,361 shares for a total of $1,779,075.70, their largest year based on trade value.